December 28, 2020 09:16 AM EST
R&D

Af­ter a ‘break­through’ be­gin­ning to 2020, lit­tle Aprea gets crushed by a PhI­II fail­ure

John Carroll

Editor & Founder

Boston-based biotech Aprea Ther­a­peu­tics $APRE start­ed the year with a promis­ing break­through ther­a­py des­ig­na­tion from the FDA for its lead p53 re­ac­ti­vat­ing pro­gram for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

A service from the Financial Times